MicroRNA-21在扩张型心肌病患者血清中表达下调

目的 本文主要探讨血清microRNA(miR)-21/155/181a/18b在具有失代偿性心力衰竭症状的扩张型心肌病(扩心病)患者中的表达水平。 方法 收集40例扩心病患者和30名健康对照者, 通过实时免疫荧光定量PCR 反应检测血清miRNA。分析miR-21等miRNA和其他临床指标如N末端脑钠肽前体(NT-proBNP)、超敏C-反应蛋白(hsCRP)、左室射血分数( LVEF%)、左室舒张末期内径(LVEDD)之间的相关性。 结果 血清miR-21在扩心病患者中的相对表达量低于健康对照组(P<0.01)。在所有的试验者中, 血清miR-21与LVEF%呈正相关, 与LVEDD呈负相关(P<0.001)。 结论 与健康对照者相比, 血清心肌重构相关的miR-21在失代偿性心力衰竭的扩心病患者中表达下调, 并与疾病的严重程度相关。
Objective To address the levels of serum miR-21/155/181a/18b in dilated cardiomyopathy (DCM) patients at a progressive heart failure stage. Methods The serum miRNAs were measured by real-time reverse-transcription PCR in 40 DCM patients and in 30 healthy controls. Pearson's correlation coefficient was used to calculate the potential correlation between miRNAs and other indicators, such as human N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP), left ventricular ejection fraction (LVEF%), and left ventricular end-diastolic diameter (LVEDD). Results Our findings revealed that serum miR-21 were significantly reduced in DCM patients compared with the healthy controls(P<0.01). We also found that serum miR-21 was positively correlated with LVEF% and negatively correlated with LVEDD (P<0.001). Conclusion The serum level of cardiac remodeling-associated miR-21 is decreased in DCM patients at a progressive heart failure stage compared to the healthy controls, which may be also related to the disease severity